Crohn Disease, IBD, Inflammatory Bowel Diseases, Ulcerative Colitis, Vitamin D3 Deficiency
Conditions
Keywords
Vitamin D3, Cholecalciferol, IBD, Inflammatory Bowel Disease, Adjunctive treatment, Crohn's Disease, Ulcerative Colitis
Brief summary
Inflammatory bowel disease ((IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC)), is a chronic, immune-mediated disease characterized by recurrent episodes of relapse. The incidence of IBD is increasing worldwide and poses as a burden that reduces quality of life and has a significant impact on health care resources. The advent of monoclonal antibodies to tumor necrosis factor-α (anti-TNF) has revolutionized treatment of IBD, improving rates of remission and reducing hospitalizations and surgeries. Nevertheless, many patients do not adequately respond to these therapies or lose response over time. Thus, there is an important need for novel immunomodulating agents to improve our ability to achieve remission. Besides its traditional role in bone homeostasis, several studies have recognized the important role Vitamin D plays in modulating the immune response, cancer, and cardiovascular disease. Specifically, Vitamin D may mediate immunity by modulating autophagy in leukocytes and regulating the gut microbiome. Thus, Vitamin D may play an important role in IBD. Furthermore, evidence suggests that the effect of vitamin D may be mediated through the TNF-α pathway, suggesting a synergy with anti-TNF therapy. This is a randomized, double blind, placebo-controlled trial to study the effect of Vitamin D3 as an adjunct therapy for patients with active CD, UC, or IBD unspecified who are undergoing anti-TNF induction therapy.
Interventions
DIETARY_SUPPLEMENTVitamin D3
Softgel capsules containing 5,000 IU cholecalciferol (Vitamin D3), sunflower oil, beef gelatin, glycerin, water
OTHERPlacebo
Sfotgel capsules containing sunflower oil, beef gelatin, glycerin, water
Sponsors
Massachusetts General Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Established diagnosis of CD, UC, or IBD-unspecified * Initiating anti-TNF therapy for IBD within 2 weeks of baseline/randomization * Other non-anti-TNF IBD medications must remain stable during the treatment period with the exception of tapering of corticosteroids. * Recent (within 6 months) objective evidence of active IBD on colonoscopy along with elevated inflammatory markers (C-reactive protein \>8 mg/L or fecal calprotectin \>150 mcg/g) * Current disease activity defined as a Harvey Bradshaw index \> 4 at baseline (week 0) for CD subjects or Simple Clinical Colitis Activity Index \> 2 at baseline (week 0) for UC subjects. * Fecal Calprotectin level \>150 mcg/g
Exclusion criteria
* Inability to provide informed consent or unwilling or unlikely to comply with the requirements of the study. * Female subjects who are pregnant, lactating, or intending to become pregnant during the study period * Known intolerance or hypersensitivity to oral vitamin D3 supplementation * Plasma 25(OH)D \> 60 ng/mL * Known celiac disease or subjects with a positive screen for celiac disease (elevated tissue transglutaminase antibodies) * Serum calcium \>11 mg/dL * History of hyperparathyroidism * History of renal calculi or chronic kidney disease * Initiation of anti-TNF treatment for extra-intestinal symptoms alone * Evidence of untreated infection (e.g. Clostridium difficile) * History of chronic pancreatitis * History of cystic fibrosis * History of gastric bypass * Presence of stoma or J-pouch
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Short Inflammatory Bowel Disease Questionnaire (SIBDQ) outcome | 14 weeks | Patients will complete the SIBDQ questionnaire to measure disease activity at baseline, week 6 and week 14. |
| stool microbiome in IBD patients | 14 weeks | Stool samples will be taken at baseline and week 14 to assess change in stool microbiome |
| serum cathelicidin levels | 14 weeks | Serum samples will be taken at baseline and week 14 to measure serum cathelicidin levels |
| HBI | 14 weeks | Patients with Crohn's Disease will complete the Harvey Bradshaw Index questionnaire to measure disease activity at baseline, week 6 and week 14 |
| SCCAI | 14 weeks | Patients with Ulcerative Colitis will complete the Simple Clinical Colitis Activity Index questionnaire to measure disease activity at baseline, week 6 and week 14 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| fecal calprotectin | 14 weeks | Stool samples will be taken at baseline and week 14 to assess change in fecal calprotectin levels |
| plasma 25(OH)D levels. | 14 weeks | Plasma samples will be taken at baseline and week 14 to measure 25(OH)D levels |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORAshwin Ananthakrishnan, MD, MPH
Massachusetts General Hospital
Outcome results
None listed